Cover Image
市場調查報告書

金磚四國的骨質疏鬆症治療藥市場:2015∼2019年

Osteoporosis Drugs Market in BRIC Nations 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 339957
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
金磚四國的骨質疏鬆症治療藥市場:2015∼2019年 Osteoporosis Drugs Market in BRIC Nations 2015-2019
出版日期: 2015年09月16日 內容資訊: 英文 68 Pages
簡介

骨質疏鬆症是由於骨骼密度降低,骨組織結構性惡化,女性大量發病。預計金磚四國的骨質疏鬆症治療藥市場2014∼2019年以年複合成長率17.43%擴大。

本報告提供金磚四國的骨質疏鬆症治療藥市場相關調查、市場現狀及至2019年的成長預測、市場規模、各市場區隔趨勢、各國趨勢,及主要供應商簡介彙整。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 骨質疏鬆症:概要

  • 骨質疏鬆症的理解
  • 流行病學和人口統計
  • 風險因素
  • 症狀
  • 診斷
  • 治療

第6章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 開發平台評估

  • 開發平台候補藥的重要資訊

第8章 各治療領域市場區隔

  • 再吸收抑制劑
  • 同化劑

第9章 治療各行的市場區隔

第10章 各地區市場區隔

第11章 各國概要

  • 中國
  • 印度
  • 俄羅斯
  • 巴西

第12章 推動市場的要素

第13章 促進要素的影響

第14章 市場課題

第16章 促進要素與課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • 主要供應商:2014年
  • 其他值得注意的供應商

第18章 主要供應商分析

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

第19章 附錄

第20章 Technavio概要

圖表

目錄
Product Code: IRTNTR7210

About osteoporosis

Osteoporosis, or porous bone, is a disease characterised by low bone density and structural deterioration of bone tissue, leading to fragile bones. This increases the risk of fractures. Osteoporosis mainly affects women, but can also affect men. In women, bone loss occurs very rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement occurs too slowly. Risk factors for osteoporosis that cannot be controlled include gender, age, body size (low body weight), ethnicity, and family history. Risk factors that can be controlled include sex hormones, medication use, calcium and vitamin intake, alcohol intake, and smoking.

Technavio's analysts forecast the osteoporosis drugs market in BRIC nations to grow at a CAGR of 17.43% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the osteoporosis drugs market in BRIC nations for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various pharmaceutical products used in the treatment of osteoporosis. Pharmaceutical products are classified as branded and generic drugs.

Technavio's report, Osteoporosis Drugs Market in BRIC Nations 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Brazil, Russia, India, and China; it also covers the landscape of the osteoporosis drugs market in BRIC nations and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key countries

  • Brazil
  • China
  • India
  • Russia

Key vendors

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

Other Prominent Vendors

  • Abiogen Pharma
  • Deltanoid Pharmaceuticals
  • F. Hoffmann La Roche
  • GlaxoSmithKline
  • IMMD
  • Ligand Pharmaceuticals
  • Pantarhei Bioscience
  • Pfizer
  • PhytoHealth
  • Radius Health
  • UPSHER-SMITH LABORATORIES
  • Zosano Pharma

Market driver

  • Increase in aging population
  • For a full, detailed list, view our report

Market challenge

  • Multiple patent expiries
  • For a full, detailed list, view our report

Market trend

  • Shift toward anabolic treatments
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Osteoporosis: An overview

  • Understanding osteoporosis
  • Epidemiology and demography
  • Risk factors
  • Symptoms
  • Diagnosis
  • Treatment

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Pipeline Assessment

  • Key information of pipeline candidates

PART 08: Market segmentation by therapeutic class

  • Antiresorptive medication
  • Anabolic medication

PART 09: Market segmentation by line of therapy

PART 10: Geographical segmentation

PART 11: Country overview

  • China
  • India
  • Russia
  • Brazil

PART 12: Market drivers

  • Rise in aging population
  • Emergence of novel agents
  • High unmet medical needs
  • Increased incidence of osteoporosis

PART 13: Impact of drivers

PART 14: Market challenges

  • Expiry of patents
  • Limited access to diagnostic tools
  • Poor patient compliance
  • Inadequate reimbursement policies
  • Lack of public awareness

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Shift toward anabolic treatment
  • Use of combination therapies
  • Increased awareness of bone health education

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Incidence of osteoporosis-related hip fractures 2012
  • Exhibit 03: Interpretation of BMD results
  • Exhibit 04: Osteoporosis drugs market in BRIC 2014-2019 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Product pipeline
  • Exhibit 07: Segmentation of osteoporosis drugs market in BRIC by therapeutic class
  • Exhibit 08: Segmentation of osteoporosis drugs market in BRIC by line of therapy
  • Exhibit 09: Segmentation of osteoporosis drugs market in BRIC by geography 2014
  • Exhibit 10: Key countries
  • Exhibit 11: Life expectancy in China (age in years)
  • Exhibit 12: Population projection of China (millions)
  • Exhibit 13: Percentage of urban and rural population in China 2013
  • Exhibit 14: Life expectancy in India (age in years)
  • Exhibit 15: Population projection of India (millions)
  • Exhibit 16: Percentage of urban and rural population in India 2013
  • Exhibit 17: Population projection of people aged 50 and above in Russia 2011 and 2050 (millions)
  • Exhibit 18: Population projection of Brazil 2011 and 2050 (millions)
  • Exhibit 19: Life expectancy in Brazil 2010 and 2050 (age in years)
  • Exhibit 20: Estimated population aged 60 and above in BRIC countries 2010-2013
  • Exhibit 21: Impact of drivers
  • Exhibit 22: Impact of drivers and challenges
  • Exhibit 23: Eli Lilly: YoY growth and revenue of Evista 2010-2014 ($ millions)
  • Exhibit 24: Eli Lilly: YoY growth and revenue of Forteo 2010-2014 ($ millions)
  • Exhibit 25: Amgen: YoY growth and revenue of Prolia 2010-2014 ($ millions)
  • Exhibit 26: Merck: YoY growth and revenue of Fosamax 2011-2014 ($ millions)
  • Exhibit 27: Novartis: YoY growth and revenue of Reclast/Aclasta 2010-2013 ($ millions)
  • Exhibit 28: Amgen: Business segmentation by revenue 2014
  • Exhibit 29: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 30: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 31: Business segmentation by revenue 2014
Back to Top